Answers are grounded in this paper and cite their sources.
Frequent intravitreal injections of anti-vascular endothelial growth factors (VEGFs) for diabetic macular oedema (DMO) pose challenges for healthcare systems, patients, and society. This study assessed the efficacy, safety, resource utilization, and costs of anti-VEGFs from a Dutch societal perspective. A systematic literature review and indirect treatment comparison (ITC) compared the efficacy and safety of aflibercept 8 mg with aflibercept 2 mg, ranibizumab, faricimab, and bevacizumab. A Markov model estimated lifetime costs for unilateral or bilateral DMO treatment over 5 years from a Dutch societal perspective. Break-even prices determined the cost-neutral price for each anti-VEGF compared to the least expensive option. The ITC found no significant differences in efficacy or safety among anti-VEGFs, leading to a cost-minimisation analysis. Over 5 years, the mean number of injections ranged from 15.0 (aflibercept 8 mg, flexible Q16 regimen) to 24.9 (bevacizumab, pro re nata regimen). Bevacizumab had the lowest 5-year per-patient cost (€80,315). Aflibercept 8 mg followed at €83,577, with a break-even price of €560 per injection (− 23% vs. current price). Aflibercept 2 mg (fixed regimen), faricimab, and ranibizumab (treat-and-extend) required price reductions of 74%, 63%, and 71%, respectively, to match bevacizumab. Despite similar efficacy and safety, differences in treatment burden were identified among the anti-VEGFs, with the more durable regimen of aflibercept 8 mg potentially reducing overall injection frequency compared to current care. Nevertheless, on the basis of current list prices, bevacizumab is the least expensive anti-VEGF for treating DMO. Aflibercept 8 mg, aflibercept 2 mg, faricimab, and ranibizumab could achieve cost-equivalence to bevacizumab if their medication prices were reduced by at least 23%, 74%, 63%, and 71%. These results could support future decision-making of healthcare providers and payers, encompassing aspects of medical costs, healthcare capacity use, and burden on patients as well as the healthcare system as a whole. Diabetic macular oedema is a common eye condition that can cause vision loss. It is effectively treated with injections of anti-vascular endothelial growth factors (anti-VEGFs), but frequent injections can be a burden for patients and healthcare systems. This study analysed existing research to compare the effectiveness, safety, resource use, and healthcare and societal costs of different anti-VEGF treatments over 5 years. The results showed that all anti-VEGFs work equally well and have similar safety profiles. However, the number of required injections varied: aflibercept 8 mg required the fewest (15.0 over 5 years), while bevacizumab required the most (24.9 over 5 years). Despite needing more injections, bevacizumab was the cheapest option, costing €80,315 per patient in a lifetime with 5 year of treatment. Aflibercept 8 mg was slightly more expensive (€83,577) but could become cost-equivalent if its medication price dropped by 23%. Other anti-VEGFs would need even larger price reductions (63–74%) to match bevacizumab’s cost. These findings highlight that while some treatments may reduce injection frequency, bevacizumab remains the least costly choice. This information can help healthcare providers and policymakers make better decisions about diabetic macular oedema treatment.
No takes yet. Share an insight, caveat, or question.
Quist et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: